Imaging AI 2024
Multiple Solutions Gaining Traction in a Crowded Market
The number of FDA-approved AI solutions for imaging has ballooned to over 300 in recent years, and during that time, adoption of various solution types (AI platforms, operational/reporting AI, and pixel AI) has also increased dramatically. Just over 50% of surveyed organizations are starting to use AI algorithms for at least one imaging use case—a significant jump from 2018, when 17% of interviewed organizations were piloting or live with an AI solution. To understand the prevalence of imaging AI adoption, this report draws from interviews with 206 US-based organizations (about 25% are imaging groups; remainder are health systems) and shares an early look at which solutions are most used and considered in this crowded market. Note that this report doesn’t explore customer satisfaction with AI solutions; KLAS intends to address this in future research.
Note: This report focuses on AI used for diagnostic imaging, workflow triage, and other imaging-specific use cases. It does not cover general AI tools, including those used for ambient speech or voice recognition.
If you don't have a login, getting started is easy.
Key Findings:
- Market Overview: Imaging AI Gaining Traction; Broader, Deeper Adoption Is on Horizon
- RapidAI & Viz.ai Most Adopted by Respondents, Followed by Aidoc & Rad AI
- AI Platforms from Aidoc & Nuance Have Strongest Consideration; Riverain Technologies Most Frequently Considered Pixel AI Solution
- Traditional Imaging IT Vendors Are Starting to Be Considered for AI Solutions
Writer
Sarah Brown
Designer
Breanne Hunter
Project Manager
Sydney Toomer
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.